Abstract
To date, the fundamental drivers of the morbidity and mortality in COVID-19 remain uncertain. Clinicians worldwide appear to be at a loss to know how to prevent and treat the severe respiratory distress in these patients effectively. Consequently, the fundamental mechanisms leading to death in high-risk patients need to be discovered and addressed with urgency. The post-mortem autopsy remains an essential part of both discovering the cause of death in a particular individual, but also in advancing the science and treatment of disease, especially in the case of novel pathogens such as SARS-CoV-2[2]. The goal of an autopsy is to discover the cause of death (COD) using a macro/microscopic investigation. Because lung weight is often affected by the cause of death and the last breath occurs very near if not at death, the evaluation of the lungs is one of the starting points of any COD investigation[3]. A comprehensive search was performed to systematically review all reported autopsy findings in COVID-19 patients with respect to lung weights and histologic findings. We then compared these findings with the results of a targeted literature review of hyaluronan in relationship to acute respiratory distress syndrome (ARDS). In total, data from 38 autopsies were identified. From this group, 36 autopsies of COVID-19 patients were selected for detailed review and statistical analysis. The average lung weight of those who were determined to have died as a result of SARS-CoV-2 was 1683g approximately 3.2 times the normal lung weight. Hyaline membranes were consistently identified on histologic sections. A review of the literature reveals that markedly elevated lung weights and hyaline membranes and have been associated with the pathophysiology of ARDS since 1967. However, the key role key of hyaluronan in driving the morbidity and mortality of the condition has heretofore not been fully recognized. We propose that the induced hyaluronan storm syndrome or IHS, is a model that addresses the heretofore perplexing respiratory failure that is the proximal cause of death. An aggressive research effort should be undertaken to discover why the majority of individuals who are exposed to the virus are minimally symptomatic, while a minority of high-risk individuals rapidly progress to respiratory failure and death.
“You may take notes for 20 years, from morning to night at the bedside of the sick, upon the diseases of the viscera, and all will be to you only a confusion of symptoms…a train of incoherent phenomena. Open a few bodies and this obscurity will disappear.” - Marie-François-Xavier Bichat (1771–1802), “The Father of Histology”[1].
Competing Interest Statement
In 2020, Michael Mong filed patent application number 63005439-Systems And Methods For Treating Corona Virus.
Funding Statement
No external funding was acquired for this manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: In 2020, Michael Mong filed patent application number 63005439- Systems And Methods For Treating Corona Virus.
Funding Source: No external funding was acquired for this manuscript.
Data Availability
The data that support the findings of this study are openly available in publicly available electronic databases. [1] Burton JL. A bite into the history of the autopsy. Forens Sci Med Pathol. 2005 Dec 1;1(4):277 84. [2] Bassat Q, Castillo P, Alonso PL, Ordi J, Menendez C. Resuscitating the Dying Autopsy. PLoS Med [Internet]. 2016 Jan 12 [cited 2020 Apr 10];13(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710495/ [3] Matoba K, Hyodoh H, Murakami M, Saito A, Matoba T, Ishida L, et al. Estimating normal lung weight measurement using postmortem CT in forensic cases. Leg Med (Tokyo). 2017 Nov;29:77:81. [4] Ashbaugh DavidG, Boyd Bigelow D, Petty ThomasL, Levine BernardE. ACUTE RESPIRATORY DISTRESS IN ADULTS. The Lancet. 1967 Aug 12;290(7511):319:23. [5] Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid 19 in Critically Ill Patients in the Seattle Region Case Series. New England Journal of Medicine. 2020 Mar 30;0(0) [6] Konig MF, Powell M, Staedtke V, Bai R Y, Thomas DL, Fischer N, et al. Targeting the catecholamine cytokine axis to prevent SARS CoV 2 cytokine storm syndrome. medRxiv. 2020 Apr 8;2020.04.02.20051565. [7] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020;395:497:506. [8] Tavassoly I, Goldfarb J, Iyengar R. Systems biology primer: the basic methods and approaches. Kolch W, Fey D, Ryan CJ, editors. Essays in Biochemistry. 2018 Oct 26;62(4):487:500. [9] Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID 19 Autopsies, Oklahoma, USA. Am J Clin Pathol [Internet]. [cited 2020 Apr 16]; Available from: https://academic.oup.com/ajcp/article/doi/10.1093/ajcp/aqaa062/5818922 [10] Modig J, Hallgren R. Increased hyaluronic acid production in lung a possible important factor in interstitial and alveolar edema during general anesthesia and in adult respiratory distress syndrome. Resuscitation. 1989 Jun;17(3):223:31. [11] Lauer ME, Dweik RA, Garantziotis S, Aronica MA. The Rise and Fall of Hyaluronan in Respiratory Diseases [Internet]. Vol. 2015, International Journal of Cell Biology. Hindawi; 2015 [cited 2020 Apr 4]. Available from: https://www.hindawi.com/journals/ijcb/2015/712507/ [12] Johnson P, Arif AA, Lee Sayer SSM, Dong Y. Hyaluronan and Its Interactions With Immune Cells in the Healthy and Inflamed Lung. Front Immunol [Internet]. 2018 [cited 2020 Apr 17];9. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2018.02787/full [13] Bell TJ, Brand OJ, Morgan DJ, Salek Ardakani S, Jagger C, Fujimori T, et al. Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biol. 2019 Jul;80:14:28. [14] McKallip RJ, Fisher M, Do Y, Szakal AK, Gunthert U, Nagarkatti PS, et al. Targeted Deletion of CD44v7 Exon Leads to Decreased Endothelial Cell Injury but Not Tumor Cell Killing Mediated by Interleukin 2 activated Cytolytic Lymphocytes. J Biol Chem. 2003 Oct 31;278(44):43818:30. [15] McKallip RJ, Hagele HF, Uchakina ON. Treatment with the Hyaluronic Acid Synthesis Inhibitor 4 Methylumbelliferone Suppresses SEB Induced Lung Inflammation. Toxins (Basel). 2013;5(10):1814:1826. doi:10.3390/toxins5101814 [16] Bray BA, Sampson PM, Osman M, Giandomenico A, Turino GM. Early Changes in Lung Tissue Hyaluronan (Hyaluronic Acid) and Hyaluronidase in Bleomycin induced Alveolitis in Hamsters. American Review of Respiratory Disease [Internet]. 2012 Dec 17 [cited 2020 Apr 19]; Available from: https://www.atsjournals.org/doi/abs/10.1164/ajrccm/143.2.284 [17] Reeves SR, Barrow KA, Rich LM, White MP, Shubin NJ, Chan CK, et al. Respiratory Syncytial Virus Infection of Human Lung Fibroblasts Induces a Hyaluronan Enriched Extracellular Matrix That Binds Mast Cells and Enhances Expression of Mast Cell Proteases. Front Immunol [Internet]. 2020 Jan 28 [cited 2020 Mar 28];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997473/ [18] Nagy N, Kuipers HF, Frymoyer AR, et al. 4 Methylumbelliferone Treatment and Hyaluronan Inhibition as a Therapeutic Strategy in Inflammation, Autoimmunity, and Cancer. Frontiers in Immunology. 2015;6. doi:10.3389/fimmu.2015.00123 [19] Liu Q, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, et al. Gross examination report of a COVID 19 death autopsy. Fa Yi Xue Za Zhi. 2020 Feb;36(1):21:3. [20] Gully PR. Pandemics, regional outbreaks, and sudden onset disasters. Healthc Manage Forum. 2020 Feb 5;0840470420901532. [21] Sekulic, M., Harper, H., Nezami, B. G., Shen, D. L., Sekulic, S. P., Koeth, A. T., Harding, C. V, Gilmore, H., & Sadri, N. (2020). Molecular Detection of SARS CoV 2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS CoV 2 Cases. American Journal of Clinical Pathology, 1:11. https://doi.org/10.1093/ajcp/aqaa091 [22] Aguiar, D., Lobrinus, J. A., Schibler, M., Fracasso, T., & Lardi, C. (2020). Inside the lungs of COVID 19 disease. International Journal of Legal Medicine. https://doi.org/10.1007/s00414 020 02318 9 [23] Fox, S. E., Akmatbekov, A., Harbert, J. L., Li, G., Brown, J. Q., & Heide, R. S. Vander. (2020). Articles Pulmonary and cardiac pathology in African American patients with COVID 19 : an autopsy series from New Orleans. The Lancet Respiratory, 2600(20), 1:6. https://doi.org/10.1016/S2213 2600(20)30243 5 [24] Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., Li, W. W., Li, V. W., Mentzer, S. J., & Jonigk, D. (2020). Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid 19. New England Journal of Medicine, NEJMoa2015432. https://doi.org/10.1056/NEJMoa2015432 [25] Wichmann, D., Sperhake, J.P., Lutgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schroder, A. S., Burdelski, C., de Heer, G., Nierhaus, A., Frings, D., Pfefferle, S., Becker, H., Bredereke Wiedling, H., de Weerth, A., Paschen, H.R., Kluge, S. (2020). Autopsy Findings and Venous Thromboembolism in Patients With COVID 19. Annals of Internal Medicine, 25(4). https://doi.org/10.7326/m20 2003 [26] Buja LM, Wolf DA, Zhao B, Akkanti B, McDonald M, Lelenwa L, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovascular Pathology. 2020 Oct;48:107233. [27] Michael A. Mong, Jacob A. Awkal, P. E. M. (2020). Accelerated hyaluronan concentration as the primary driver of morbidity and mortality in high-risk COVID-19 patients: with therapeutic introduction of an oral hyaluronan inhibitor in the prevention of Induced Hyaluronan Storm Syndrome
Abbreviations
- COVID-19
- novel coronavirus disease 2019
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- HA
- hyaluronic acid or hyaluronan
- IHS
- induced hyaluronan storm
- CSS
- cytokine storm syndrome
- SEB
- staphylococcal enterotoxin B
